In DLBCL and MM, this can include mutations in receptors (i.e., CD79 of the B cell receptor), adaptors (e.g., MYD88, CARMA1, BCL10) and pathway modulators (A20, CYLD, TRAFs, BTK, BIRC2/3) [15,16,17,18,19]. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.